| Browse All

PepGen Inc. (PEPG)

Healthcare | Biotechnology | Boston, United States | NasdaqGS
1.66 USD -0.08 (-4.335%) ⇩ (April 21, 2026, 12:09 p.m. EDT)

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:12 a.m. EDT

Extreme short-term downside protection bets vs. weak fundamentals. Despite a NASDAQ 100M+ market cap and a dollar-value put spread positioning the downside, the stock is trapped between catastrophic R&D burn (-$81M oper cash flow), negative earnings history, and severe legal threats (Pomerantz lawsuit). The high short ratio and negative forecasting model stats confirm a 'value trap' scenario where technical support (short put gamma) is heavy but fundamental reality (heavy losses, trial data mixed results) makes a long-term thesis unproven.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.382793
AutoTheta0.383376
AutoETS0.383550
AutoARIMA0.398283

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 26%
H-stat 50.91
Ljung-Box p 0.000
Jarque-Bera p 0.013
Excess Kurtosis -0.72
Attribute Value
Sector Healthcare
Debt to Equity Ratio 11.533
Market Cap 114,385,816
Forward P/E -1.42
Beta 2.34
Website https://www.pepgen.com

As of April 19, 2026, 12:12 a.m. EDT: Options data reveals extreme sentiment divergence. April puts (April 17) are heavily skewed towards In-The-Money (ITM) positions at strikes 2.0 and 5.0, with massive open interest (171k and 15k respectively) compared to negligible call ITM interest. Conversely, May 15 and August 21 calls show significant unhedged OTM open interest, indicating speculative bullish positioning for a rebound toward the $5–$10 analyst targets. However, the overwhelming ITM put blockage in the near term (April) signals a strong speculative defense of the downside, suggesting traders expect a decline or stagnation near current multi-year lows.


Info Dump

Attribute Value
52 Week Change 0.06790125
Address1 321 Harrison Avenue
Address2 8th Floor
All Time High 20.0
All Time Low 0.88
Ask 1.66
Ask Size 8
Average Daily Volume10 Day 1,408,010
Average Daily Volume3 Month 1,363,080
Average Volume 1,363,080
Average Volume10Days 1,408,010
Beta 2.342
Bid 1.25
Bid Size 2
Book Value 2.141
City Boston
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.655
Current Ratio 11.938
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.7499
Day Low 1.64
Debt To Equity 11.533
Display Name PepGen
Earnings Timestamp 1,772,658,000
Earnings Timestamp End 1,778,788,800
Earnings Timestamp Start 1,778,788,800
Ebitda -92,215,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.129
Enterprise Value -11,882,545
Eps Current Year -1.165
Eps Forward -1.164
Eps Trailing Twelve Months -2.12
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.5727
Fifty Day Average Change -2.9177
Fifty Day Average Change Percent -0.6380694
Fifty Two Week Change Percent 6.7901254
Fifty Two Week High 7.8
Fifty Two Week High Change -6.1450005
Fifty Two Week High Change Percent -0.7878206
Fifty Two Week Low 1.01
Fifty Two Week Low Change 0.645
Fifty Two Week Low Change Percent 0.6386138
Fifty Two Week Range 1.01 - 7.8
Financial Currency USD
First Trade Date Milliseconds 1,651,843,800,000
Float Shares 36,971,152
Forward Eps -1.164
Forward P E -1.4218212
Free Cashflow -49,845,500
Full Exchange Name NasdaqGS
Full Time Employees 56
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.00715
Held Percent Institutions 0.92627996
Implied Shares Outstanding 69,115,292
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Long Name PepGen Inc.
Market us_market
Market Cap 114,385,816
Market State REGULAR
Max Age 86,400
Message Board Id finmb_1677986244
Most Recent Quarter 1,767,139,200
Net Income To Common -89,655,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 119,915,031
Number Of Analyst Opinions 7
Open 1.74
Operating Cashflow -81,635,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 781 797 0979
Previous Close 1.73
Price Eps Current Year -1.4206009
Price Hint 4
Price To Book 0.7730032
Profit Margins 0.0
Quick Ratio 11.739
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.07500005
Regular Market Change Percent -4.335263
Regular Market Day High 1.7499
Regular Market Day Low 1.64
Regular Market Day Range 1.64 - 1.7499
Regular Market Open 1.74
Regular Market Previous Close 1.73
Regular Market Price 1.655
Regular Market Time 1,776,787,796
Regular Market Volume 277,084
Return On Assets -0.36028
Return On Equity -0.67393994
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 69,115,292
Shares Percent Shares Out 0.0498
Shares Short 3,438,459
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 2,654,341
Short Name PepGen Inc.
Short Percent Of Float 0.0641
Short Ratio 1.71
Source Interval 15
State MA
Symbol PEPG
Target High Price 20.0
Target Low Price 3.0
Target Mean Price 10.28571
Target Median Price 10.0
Total Cash 148,456,000
Total Cash Per Share 2.148
Total Debt 17,004,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.12
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.98925
Two Hundred Day Average Change -2.33425
Two Hundred Day Average Change Percent -0.58513504
Type Disp Equity
Volume 277,084
Website https://www.pepgen.com
Zip 2,118